Illumina (ILMN:NASDAQ) Annual Reports & Investor Relations Material

Overview

San Diego-based Illumina, Inc. is a life science tools and integrated systems company that has been a key player in the analysis of genetic variation and function. Operating through its Core Illumina and GRAIL segments, the company offers sequencing and array-based instruments and consumables, such as reagents, flow cells, library preparation, whole-genome sequencing kits, and targeted resequencing kits. Illumina also provides genotyping and product support services, and in recent years, it has broken new ground with Galleri, its multi-cancer early detection test. The company caters to a diverse clientele comprising genomic research centers, academic institutions, government laboratories, hospitals, and biotechnology firms, among others. It markets and distributes its products primarily in North America, Europe, Latin America, and the Asia-Pacific region. Illumina, Inc. was founded in 1998 and has since been instrumental in empowering scientists and researchers around the world with its cutting-edge products and services.

Frequently Asked Questions

What is Illumina's ticker?

Illumina's ticker is ILMN

What exchange is Illumina traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Illumina's headquarters?

They are based in San Diego, California

How many employees does Illumina have?

There are 5001-10,000 employees working at Illumina

What is Illumina's website?

It is illumina.com

What type of sector is Illumina?

Illumina is in the Healthcare sector

What type of industry is Illumina?

Illumina is in the Biotechnology industry

Who are Illumina's peers and competitors?

The following five companies are Illumina's industry peers:

- Molecular Templates, Inc.

- Bellicum Pharmaceuticals Inc

- Esperion Therapeutics

- Momenta Pharmaceuticals Inc.

- Veracyte